McKesson stock buyback
Executive Summary
Wholesaler to repurchase up to 2 mil. additional shares of its common stock on the open market. A previous plan to purchase 1.5 mil. shares is nearing completion, the firm said. In addition, McKesson will sell up to 1.6 mil. treasury shares to the employee stock ownership plan. The company currently has about 41 mil. shares outstanding.
You may also be interested in...
Pfizer Eyes EU Pegfilgrastim Roll-Out By 1 April As US Launch Is Confirmed
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.
COVID-19: EU Dexamethasone Taw Filing Pulled
The withdrawal of the marketing authorization application for Dexamethasone Taw as a treatment for COVID-19 patients was revealed today in the January meeting agenda of the European Medicines Agency’s human medicines committee, the CHMP.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: